Egetis Therapeutics to Participate in Upcoming Investor Conferences

Egetis Therapeutics, a Swedish-based pharmaceutical company, will participate in two upcoming investor conferences in September, providing updates on its lead drug candidate and broader strategic plans.

Nicklas Westerholm, CEO of Egetis Therapeutics, will deliver a fireside chat at the Cantor Global Healthcare Conference on September 11, 2026, at the Waldorf Astoria in New York. The session, scheduled from 9:10 to 9:40 a.m. EDT (15:10 to 15:40 CEST), will offer insights into the company’s initiatives and progress.

On September 16, 2026, Westerholm will also participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, held at the New York Marriott Marquis. The event will take place from 1:50 to 2:20 p.m. EDT (19:50 to 20:20 CEST).

Egetis Therapeutics, known for its innovative approach to orphan drug treatments, has made significant strides in bringing Emcitate® (tiratricol) to patients. In February 2025, the European Commission approved Emcitate® as the first and only treatment for MCT8 deficiency, a rare and debilitating condition. The company initiated the launch of Emcitate® in Germany on May 1, 2025. The U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for Emcitate® for the treatment of MCT8 deficiency, granting the application Priority Review. The PDUFA target action date is set for September 28, 2026.

The NDA for Emcitate® is based on clinical data from several trials, including Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study, and the US Expanded Access Program. Tiratricol, the active ingredient in Emcitate®, holds Orphan Drug Designation for MCT8 deficiency and resistance to thyroid hormone beta (RTH-beta) in both the US and the EU, with distinct patient populations. The drug has also received Breakthrough Therapy Designation and Rare Pediatric Disease Designation, which could lead to a Priority Review Voucher in the US upon approval.

Additionally, Egetis Therapeutics is developing Aladote® (calmangafodipir), a first-in-class drug candidate designed to reduce the risk of acute liver injury from paracetamol (acetaminophen) overdose. While the company has completed a proof of principle study, the development program for Aladote® has been placed on hold.

Egetis Therapeutics, listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX), continues to face uncertainties in its market strategies and regulatory landscape. The company’s forward-looking statements, which include expectations for the commercialization and availability of Emcitate® in the US, potential monetization of the Rare Pediatric Disease Priority Review Voucher, and broader strategic plans, are subject to significant risks and uncertainties. These include commercial launch and market acceptance risks, the establishment of adequate infrastructure, and regulatory and competitive challenges.